Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HALT: Human Albumin to Reduce Kidney Dysfunction After Liver Transplantation
2024-514804-14-00Phase 4Authorised
- Sponsor
- CHU Rennes
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of albumin (human) in liver transplant (2 arms), sponsored by CHU Rennes. Primary endpoint: Acute kidney injury incidence (first 7 days). Planned start Jan 2025; status: authorised.
02
Drugs
albumin (human)
03
Conditions
liver transplant
Beyond the preview
Go deeper on 2024-514804-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514804-14-00.